within Pharmacolibrary.Drugs.ATC.J;

model J06BB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 45 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.0062,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Anti-D (Rh) immunoglobulin is a human IgG antibody preparation used for prevention of RhD alloimmunization, primarily in Rh-negative pregnant women to prevent hemolytic disease of the fetus and newborn. It is also used after incompatible transfusions or other situations with potential Rh antigen exposure. The drug is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult healthy volunteers after intramuscular injection of anti-D immunoglobulin.</p><h4>References</h4><ol><li><p>Jilma-Stohlawetz, P, et al., &amp; Jilma, B (2005). Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. <i>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</i> 33(2) 135–140. DOI:<a href=&quot;https://doi.org/10.1016/j.transci.2005.02.006&quot;>10.1016/j.transci.2005.02.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16112906/&quot;>https://pubmed.ncbi.nlm.nih.gov/16112906</a></p></li><li><p>Bichler, J, et al., &amp; Andresen, I (2003). Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. <i>BJOG : an international journal of obstetrics and gynaecology</i> 110(1) 39–45. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12504934/&quot;>https://pubmed.ncbi.nlm.nih.gov/12504934</a></p></li><li><p>Tiblad, E, et al., &amp; Westgren, M (2012). Pharmacokinetics of 250 μg anti-D IgG in the third trimester of pregnancy: an observational study. <i>Acta obstetricia et gynecologica Scandinavica</i> 91(5) 587–592. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0412.2012.01377.x&quot;>10.1111/j.1600-0412.2012.01377.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22352370/&quot;>https://pubmed.ncbi.nlm.nih.gov/22352370</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J06BB01;
